Chugai Pharmaceutical (OTCMKTS:CHGCY) Posts Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) issued its quarterly earnings data on Thursday. The company reported $0.25 earnings per share for the quarter, Zacks reports. The firm had revenue of $2.25 billion for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.22%.

Chugai Pharmaceutical Trading Down 0.1%

Shares of CHGCY stock opened at $28.55 on Friday. The stock has a 50 day moving average of $26.81 and a two-hundred day moving average of $24.46. The company has a market capitalization of $93.96 billion, a P/E ratio of 32.82 and a beta of 0.63. Chugai Pharmaceutical has a 12 month low of $19.50 and a 12 month high of $31.26.

Analysts Set New Price Targets

Separately, UBS Group raised Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company currently has an average rating of “Strong Buy”.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.